Pre-Open Stock Movers 03/19: (FOLD) (GES) (SFS) Higher; (CNCE) (WSM) (EBAY) Lower (more...)
- Wall Street closes rollercoaster week sharply lower
- Invesco (IVZ) Reportedly in Talks to Merge With State Street's (STT) Asset Management Business, Citi Sees More Cons than Pros
- FDA Votes "No" on Pfizer (PFE) Booster for 16+ Age Group, 2 Yes 16 No
- Jefferies Raises Price Targets on Alphabet (GOOGL) and Facebook (FB) as They Are Still Inexpensive Relative to Growth, Reiterates Snap (SNAP) as a Best Growth Idea
- Tesla (TSLA) Could Deliver 900K EV Units This Year and 1.3M in 2022 - Wedbush
Amicus Therapeutics (Nasdaq: FOLD) 26.4% HIGHER; announced that it has met very recently with regulatory authorities in Europe and the U.S. to discuss the approval pathways for the oral small molecule pharmacological chaperone migalastat HCl ("migalastat") as a precision medicine monotherapy for Fabry patients who have amenable genetic mutations.
Coronado Biosciences, Inc. (Nasdaq: CNDO) 11.1% HIGHER; announced today the formation of a new company, Mustang Therapeutics, Inc. Mustang will initially focus on the preclinical and clinical development, as well as commercialization of proprietary Chimeric Antigen Receptor (CAR-T) technology. This portfolio of CAR-T cells was developed by Dr. Stephen Forman, Director, T cell Therapeutics Research Laboratory and the Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, and Dr. Christine Brown, Associate Director, T cell Therapeutics Research Laboratory and Associate Research Professor. The deal is valued in excess of $40 million for the development of these CAR-T cells via up-front and milestone payments to City of Hope. It is anticipated that the first two CAR-T cells from this partnership will begin enrollment in human clinical trials at the City of Hope this year.
Guess? (NYSE: GES) 10.3% HIGHER; reported Q4 EPS of $0.63, $0.06 better than the analyst estimate of $0.57. Revenue for the quarter came in at $696.7 million versus the consensus estimate of $704.6 million. North American Retail revenues decreased 4%; retail comp sales including e-commerce decreased 5% in U.S. dollars and 3% in constant currency; European revenues decreased 16% in U.S. dollars and 5% in constant currency; Asian revenues decreased 9% in U.S. dollars and 7% in constant currency. The company sees Q1 EPS of $0.06 to a ($0.03), versus the consensus of ($0.03). The company sees FY 2016 EPS of $0.75 to $0.95 versus the consensus of $1.04.
Heron Therapeutics, Inc. (NASDAQ: HRTX) 10.8% HIGHER; announced today positive results from a Phase 1 clinical study of HTX-011, Herons lead product candidate for the prevention of post-operative pain. HTX-011, which utilizes Herons proprietary Biochronomer® drug delivery technology, is a long-acting formulation of the local anesthetic bupivacaine in combination with the anti-inflammatory meloxicam.
Smart & Final Stores (NYSE: SFS) 10.1% HIGHER; reported Q4 EPS of $0.16, $0.05 better than the analyst estimate of $0.11. Revenue for the quarter came in at $839.3 million versus the consensus estimate of $820.46 million. It reported comparable store sales growth of 7.8%.
Shoe Carnival (NASDAQ: SCVL) 9.4% HIGHER; reported Q4 EPS of $0.15, $0.06 better than the analyst estimate of $0.09. Revenue for the quarter came in at $227.6 million versus the consensus estimate of $220.2 million. Comparable store sales increased 9.5 percent in the fourth quarter of fiscal 2014, exceeded the Company’s guidance for the quarter. Shoe Carnival sees FY2015 EPS of $1.40-$1.48, versus the consensus of $1.45. Shoe Carnival sees FY2015 revenue of $977-991 million, versus the consensus of $995.7 million.
Synthetic Biologics (NYSE: SYN) 9.3% HIGHER; announced positive pharmacokinetics (PK) results from both the Phase 1a and 1b studies of SYN-004, which is being developed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection.
NQ Mobile (NYSE: NQ) 7.9% HIGHER; reported Q4 EPS of $0.03, $0.01 better than the analyst estimate of $0.02. Revenue for the quarter came in at $89.7 million versus the consensus estimate of $83 million.
Concert Pharma (NASDAQ: CNCE) 6.2% LOWER; announced the pricing of an underwritten public offering of 3,300,000 shares of its common stock at a public offering price of $15.15 per share.
Chesapeake Energy (NYSE: CHK) 3.8% LOWER; Sterne Agee downgraded from Neutral to Underperform with a price target of $9.00
Tekmira Pharmaceuticals (Nasdaq: TKMR) 3.3% LOWER; announced that the Company is offering to sell 6,000,000 common shares in an underwritten public offering. Tekmira also expects to grant the underwriters a 30‐day option to purchase up to an additional 900,000 common shares.
Williams-Sonoma (NYSE: WSM) 3.2% LOWER; reported Q4 EPS of $1.52, in-line with the analyst estimate of $1.52. Revenue for the quarter came in at $1.55 billion versus the consensus estimate of $1.57 billion. Comparable brand revenue grew 5.1 percent. Williams-Sonoma sees FY2015 EPS of $3.35-$3.45, versus the consensus of $3.63. Williams-Sonoma sees FY2015 EPS of $0.40-$0.45, versus the consensus of $0.54.
eBay (NASDAQ: EBAY) 2.6% LOWER; Piper Jaffray downgraded from Neutral to Underweight
Tilly's, Inc. (NYSE: TLYS) 1.3% HIGHER; reported Q4 EPS of $0.25, $0.03 better than the analyst estimate of $0.22. Revenue for the quarter came in at $15.8 million versus the consensus estimate of $151.76 million. Comparable store sales, which include e-commerce sales, increased 2.9% compared to the same 13-week period in 2013. Tilly's, Inc. sees Q1 2015 EPS of $0.03-$0.05, versus the consensus of $0.04.
Biogen (NASDAQ: BIIB) 1.2% HIGHER; Credit Suisse lifts price target to $500
Cintas Corporation (NASDAQ: CTAS) 1% HIGHER; reported Q3 EPS of $0.85, $0.07 better than the analyst estimate of $0.78. Revenue for the quarter came in at $1.11 billion versus the consensus estimate of $1.11 billion. Cintas Corporation sees FY2015 EPS of $3.31-$3.34, versus prior guidance of $3.20-$3.25 and the consensus of $3.27. Cintas Corporation sees FY2015 revenue of $4.46-4.49 billion, versus prior guidance of $4.45-4.50 billion and the consensus of $4.49 billion.
Tesla (NASDAQ: TSLA) 0.5% HIGHER; Baird would be aggressive buyers on weakness.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cisco Systems (CSCO) Upgraded to Outperform at Credit Suisse, Other Analysts Raise PTs Following Bullish Investor Day
- Prenetics, a Global Leader in Genomic and Diagnostic Testing, to Become Publicly Traded on the Nasdaq via Merger with Adrian Cheng's Artisan Acquisition Corp.
- Vicarious Surgical Business Combination Approved; Stock to Begin Trading on the New York Stock Exchange as “RBOT”
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesCredit Suisse, Piper Jaffray, Robert W Baird, Sterne Agee, Tesla, Pre-Open Losers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!